Technical Analysis for MDCO - The Medicines Company

Grade Last Price % Change Price Change
grade F 20.0 0.25% 0.05
MDCO closed up 0.25 percent on Friday, January 18, 2019, on 48 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical MDCO trend table...

Date Alert Name Type % Chg
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Spinning Top Other 0.25%
Jan 17 Multiple of Ten Bearish Other 0.25%
Jan 17 Weak + Overbought Other 0.25%
Jan 17 Overbought Stochastic Strength 0.25%
Jan 16 NR7 Range Contraction 1.01%
Jan 16 Multiple of Ten Bearish Other 1.01%
Jan 16 Weak + Overbought Other 1.01%
Jan 16 Weak, Overbought and Reversal Signs Reversal 1.01%

Older signals for MDCO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, as well as for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trial for the treatment of acute bacterial skin and skin structure infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company's products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS); MDCO-216, a novel biologic product that is in Phase I trial to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program, which is in Phase I trial for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
Is MDCO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 41.57
52 Week Low 16.69
Average Volume 1,406,089
200-Day Moving Average 30.3749
50-Day Moving Average 20.4328
20-Day Moving Average 18.986
10-Day Moving Average 19.718
Average True Range 1.0897
ADX 13.13
+DI 15.2054
-DI 16.0608
Chandelier Exit (Long, 3 ATRs ) 16.9709
Chandelier Exit (Short, 3 ATRs ) 19.9591
Upper Bollinger Band 20.728
Lower Bollinger Band 17.244
Percent B (%b) 0.79
BandWidth 18.350363
MACD Line -0.1381
MACD Signal Line -0.4083
MACD Histogram 0.2702
Fundamentals Value
Market Cap 1.44 Billion
Num Shares 72.1 Million
EPS -10.00
Price-to-Earnings (P/E) Ratio -2.00
Price-to-Sales 20.03
Price-to-Book 14.81
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.31
Resistance 3 (R3) 21.16 20.59 21.09
Resistance 2 (R2) 20.59 20.25 20.66 21.01
Resistance 1 (R1) 20.29 20.05 20.44 20.44 20.94
Pivot Point 19.72 19.72 19.79 19.79 19.72
Support 1 (S1) 19.42 19.38 19.57 19.57 19.06
Support 2 (S2) 18.85 19.18 18.92 18.99
Support 3 (S3) 18.55 18.85 18.91
Support 4 (S4) 18.70